Summary
Genotoxic effects are hardly assessable in an exposed population but are generally considered to be serious due to their unpredictable effects on subsequent generations and to the link between genotoxicity and cancer. Lack of knowledge about a genotoxic/carcinogenic potential has to be stated for numerous compounds which are often in pharmaceutical use known for a long time. A thorough testing programme like it is done for new compounds is essential for such compounds that are not completely unsuspicious with respect to being reactive with macromolecules or that have the potential to generate reactive metabolites in the body.
Paracetamol, anthraquinone-containing preparations, and griseofulvin are examples for pharmaceuticals that have been in use for a long time but for which genotoxicity testing revealed a possible deleterious potential only recently. The Federal Health Office/Federal Institute for Drugs and Medical Devices therefore imposed new studies upon companies marketing these compounds in the last years. These studies in part led to a more thorough description of possible adverse effects or even restrictions for use. Paracetamol exhibits a genotoxic potential in vitro and in vivo probably via indirect, cytotoxicity or enzyme inhibition-mediated effects. Further studies will have to clarify whether a threshold could be established and whether effects do not occur at therapeutic dose levels. Genotoxicity data on the mixed group of anthraquinones reveal positive and negative findings. Compounds such as lucidin, danthron, emodin supposedly have a genotoxic and carcinogenic potential. Further studies with anthraquinone-containing plant preparations will have to clarify the content and genotoxic activity of the preparations and the active ingredients. Lucidin- and danthron-contaning preparations are currently no longer in use now whereas restrictions apply for other anthraquinone-containing laxatives. Griseofulvin is acknowledged in the meantime as an aneugen for somatic and germ cells. It is in vitro effective in concentrations that correspond to therapeutic plasma levels.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Ames BN, Durston WE, Yamasaki E, Lee FD (1973) Carcinogens are mutagens: a simple test system combining liver homogenates for activation and bacteria for detection. Proc Natl Acad Sci USA 70: 2281–2285
Blömeke B, Poginsky B, Schmutte C, Marquardt H, Westendorf J (1992) Formation of genotoxic metabolites from anthraquinone glycosides, present in Rubia tinctorum L., Mutation Res 265: 263–272
Bösch R, Friedrich U, Lutz WK, Brocker E, Bachmann M, Schlatter Ch (1987) Investigations on DNA binding in rat liver and in Salmonella and on mutagenicity in the Ames test by emodin, a natural anthraquinone. Mutation Res 188: 161–168
Brown J, Brown R (1976) Mutagenesis by 9–10-anthraquinones and related compounds in salmonella typhimurium. Mutation Res 40: 203–224
Bruce WB, Heddle JA (1979) The mutagenic activity of 61 agents as determined by the micronucleus, salmonella, and sperm abnormality assay. Can J Genet Cytol 21: 319–334
DeCarli L, Larizza L (1988) Griseofulvin. Mutation Res 195: 91–126
Hongslo JK, Bjoernstad C, Schwarze P, Holme JA (1989) Inhibition of replicative DNA synthesis by paracetamol in V79 Chinese hamster cells. Toxic In Vitro 3: 13–20
Hongslo JK, Bjoerge C, Schwarze PE, Broegger A, Mann G, Thelander L, Holme JA (1990) Paracetamol inhibits replicative DNA synthesis and induces sister chromatid exchange and chromosomal aberrations by inhibition of ribonucleotid reductase. Mutagenesis 5: 475–480
Hongslo JK, Broegger A, Bjoerge C, Holme JA (1991) Increased frequency of sister chromatid exchange and chromatid breaks in lymphocytes after treatment of human volunteers with therapeutic doses of paracetamol. Mutation Res 261: 1–8
Hongslo JK, Smith CV, Brunborg G, Soederlund EJ, Holme JA (1994) Geno- toxicity of paracetamol in mice and rats. Mutagenesis 9: 93–100
Hurst EW, Paget GE (1963) Protoporphyrin, cirrhosis and hepatoma in the livers of mice given griseofulvin. Brit J Derm 75: 105–112
Kawasaki Y, Goda Y, Yoshihira K (1992) The mutagenic constituents of Rubia tinctorum. Chem Pharm Bull 40: 1504–1509
Kirkland DJ, Dresp JH, Marshall RR, Baumeister M, Gerloif C, Gocke E (1992) Normal chromosome aberration frequencies in peripheral lymphocytes of healthy human volunteers exposed to a maximum daily dose of paracetamol in a double blind trial. Mutation Res 279: 181–194
Kocisová J, Rossner P, Binková B, Bavorová H, Srám RJ (1988) Mutagenicity studies on paracetamol in human volunteers. I. Cytogenetic analysis of peripheral lymphocytes and lipid peroxidation in plasma. Mutation Res 209: 161–165
Krivobok S, Seigle-Murandi F, Steiman R, Marzin DR, Betina V (1992) Mutagenicity of substituted anthraquinones in the Ames/Salmonella microsome system. Mutation Res 279: 1–8
Mailhes JB, Marchetti F, Aardema MJ (1993) Griseofiilvin-induced aneuploidy and meiotic delay in mouse oocytes: effect of dose and harvest time. Mutation Res 300: 155–163
Marchetti F, Mailhes JB (1994) Variation of mouse oocyte sensitivity to griseofulvin-induced aneuploidy and meiotic delay during the first meiotic division. Env Molec Mutagen 23: 179–185
Mori H, Sugie S, Niwa K, Takahashi M, Kawai K (1985) Induction of intestinal tumors in rats by chiysazin. Brit J Cancer 52: 781–783
Mori H, Sugie S, Niwa K, Yoshimi N, Tanaka T, Hirono I (1986) Carcinogenicity of chiysazin in large intestine and liver of mice. Jpn J Cancer Res 77: 871–876
Mori H, Yoshimi N, Iwata H, Mori Y, Hara A, Tanaka T, Kawai K (1990) Carcinogenicity of natural occuring l-hydroxyanthraquinone in rats: induction of large bowel, liver and stomach neoplasms. Carcinogenesis 11: 799–802
Müller L, Kasper P, Madie S (1991) Further investigations on the clastogenicity of paracetamol and acetylsalicylic acid in vitro. Mutation Res 263: 83–92
National Toxicology Program Report No. 394, 1991
Poginsky B (1991) Evaluation of DNA-binding activity of hydroxyanthaquinones occuring in Rubia tinctorum L., Carcinogenesis 12: 1265–1271
Ray SD, Kamendulis LM, Gurule MW, Yorkin RD, Corcoran GB (1990) Ca2+ antagonists inhibit DNA fragmentation and toxic cell death induced by acetaminophen. In: Biological Reactive Intermediates IV, Widmer CM, et al. (Eds,), Plenum Press, New York, pp. 699–705
Rustia M, Shubik P (1978) Thyroid tumours in rats and hepatomas in mice after griseofulvin treatment. Brit J Cancer 38: 237–249
Schäfer-Korting M, Korting HC, Mutschier E (1985) Human plasma and skin blister fluid levels of griseofulvin following a single oral dose. Eur J Clin Pharmacol 29: 109–113
Siegers CP, von Hertzberg-Lottin E, Otte M, Schneider B (1993) Anthranoid laxative abuse — a risk for colorectal cancer? Gut 34: 1099–1101
Shen W, Kamendulis LM, Ray SD, Corcoran GB (1992) Acetaminophen-induced cytotoxicity in cultured mouse hepatocytes: Effects of Ca2+-endonuclease, DNA-repair, and glutathion depletion inhibitors on DNA fragmentation and cell death. Toxicol Appl Pharmacol 112: 32–40
Seelbach A, Fissler B, Strohbusch A, Madie S (1993) Development of a modified micronucleus assay in vitro for detection of aneugenic effects. Toxic in vitro 7: 185–193
Sokolowski AL, Montin G, Nilsson A, Olofsson I-M, Sjöberg P (1992) Two-year carcinogenicity study with senna in the rat. Abstract, Sixth Int Congress of Tox, Rome, 28.6.-3.7.92
Tikkanen L, Matsushima T, Natori S (1983) Mutagenicity of anthraquinones in the Salmonella preincubation test. Mutation Res 116: 297–304
Venkataram S, Rogers JA (1988) Characteristics of drug-phospholipid coprecipi- tates II: bioavailability studies of griseofulvin in rats. J Pharm Sci 77: 933–936
Westendorf J, Poginsky B, Marquardt H, Groth G, Marquardt H (1988) The genotoxicity of lucidin, a natural component of Rubia tinctorum L., and lucidinyl-ether, a component of ethanolic rubia extracts. Cell Biol Toxicol 4: 225–239
Westendorf J, Marquardt H, Poginsky B, Dominiak M, Schmidt J, Marquardt H (1990) Genotoxicity of natural occurring hydroxyanthraquinones. Mutation Res 240: 1–12
Yokoo H, Craig RM, Harwood TR, Cochrane C (1979) Griseofulvin-induced cholestasis in swiss albino mice. Gastroenterology 77: 1082–1087
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Müller, L., Kasper, P. (1995). OTC Pharmaceuticals and Genotoxicity Testing: The Paracetamol, Anthraquinone, and Griseofulvin Cases. In: Degen, G.H., Seiler, J.P., Bentley, P. (eds) Toxicology in Transition. Archives of Toxicology, vol 17. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-79451-3_26
Download citation
DOI: https://doi.org/10.1007/978-3-642-79451-3_26
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-79453-7
Online ISBN: 978-3-642-79451-3
eBook Packages: Springer Book Archive